Suven Life gets product patents from New Zealand, US
New Delhi: Suven Life Sciences said it has been granted a product patent by New Zealand and the US, each corresponding to a new chemical entity (NCE) for treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034, the company said in a BSE filing.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need, with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia and sleep disorders such as Narcolepsy, it added.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd